Clinical Trial Update: Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating neoadjuvant afatinib for potentially resectable stage III EGFR mutation-positive lung adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Lung Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Lung Adenocarcinoma Stage III, EGFR Gene Mutation | Phase 2 | Status: COMPLETED